All In Biotech

Drug Trial Radar · NCT03854032

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Window-of-opportunity Trial of Nivolumab and BMS-986205 in Patients With Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

65

Actual

Start

Apr 9, 2019

Primary completion

Feb 10, 2022

Study completion Mar 14, 2023

Sponsor

Lead sponsor
Thomas Jefferson UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bristol-Myers Squibb
First posted
Feb 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well nivolumab works, with or without BMS986205, in treating patients with stage II-IV squamous cell cancer of the head and neck. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. BMS986205 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab with BMS986205 may work better than nivolumab alone in treating patients with squamous cell cancer of the head and neck.

Conditions

  • Lip
  • Oral Cavity Squamous Cell Carcinoma
  • Pharynx
  • Larynx
  • Squamous Cell Carcinoma

Interventions

  • NivolumabBiological

    Given IV

  • IDO1 Inhibitor BMS-986205Biological

    Given PO

  • Therapeutic Conventional SurgeryProcedure

    Undergo Surgery

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective ResponseTime frame: At 5 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Ohio State University

    Columbus, Ohio

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.